



# Subway

## Reference List

Barbera J, Jansa P, Klings E, et al. Ralinepag phase II open-label extension study in patients with pulmonary arterial hypertension. *Adv Ther.* 2024;41(3):1062-1074. doi:10.1007/s12325-023-02769-7

Benza RL, Gomberg-Maitland M, Elliott CG, et al. Predicting survival in patients with pulmonary arterial hypertension: The REVEAL Risk Score Calculator 2.0 and comparison with ESC/ERS-based risk assessment strategies. *Chest.* 2019;156(2):323-337. doi:10.1016/j.chest.2019.02.004

Bousseau S, Fais RS, Gu S, Frump A, Lahm T. Pathophysiology and new advances in pulmonary hypertension. *BMJ Med.* 2023;2(1):e000137. doi.org/10.1136/bmjmed-2022-000137

Chin KM, Gaine SP, Gerges C, et al. Treatment algorithm for pulmonary arterial hypertension. *Eur Respir J.* 2024;64(4):2401325. doi:10.1183/13993003.01325-2024

Deshwal H, Weinstein T, Salyer R, et al. Long-term impact of add-on sequential triple combination therapy in pulmonary arterial hypertension: Real world experience. *Ther Adv Respir Dis.* 2023;17:17534666231199693. doi:10.1177/17534666231199693

DuBrock HM, Germack HD, Gauthier-Loiselle M, et al. Economic burden of delayed diagnosis in patients with pulmonary arterial hypertension (PAH). *Pharmacoecon Open.* 2023;8(1):133-146. doi:10.1007/s41669-023-00453-8

Eichstaedt CA, Belge C, Chung WK et al. Genetic counselling and testing in pulmonary arterial hypertension: a consensus statement on behalf of the International Consortium for Genetic Studies in PAH. *Eur Respir J.* 2023;61(2):2201471. doi:10.1183/13993003.01471-2022

Fernandes CJ, Steigner ML, Piazza G, Goldhaber SZ. Collaborative cardiology and pulmonary management of pulmonary hypertension. *Chest.* 2019;156(2):200-202. doi:10.1016/j.chest.2019.04.099

Frantz RP, McLaughlin VV, Sahay S, et al. Seralutinib in patients with pulmonary arterial hypertension (TORREY): a randomised, double-blind, placebo-controlled phase 2 trial. *Lancet Respir Med.* 2024;12(7):523-534. doi:10.1016/S2213-2600(24)00072-9

Galiè N, Barberà JA, Frost AE, et al. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. *N Engl J Med.* 2015;373(9):834-844. doi:10.1056/NEJMoa1413687

Gillmeyer KR, Johnson SW, Bolton RE, McCullough MB, Wiener RS. Organization of pulmonary hypertension care in non-expert care settings: Lessons learned from a multi-site study. *Health Serv Res.* 2022;58(3):663-673. doi:10.1111/1475-6773.14114

Gossamer Bio, Inc. Efficacy and safety of seralutinib in adult subjects with pulmonary arterial hypertension (PAH). Updated June 4, 2025. Accessed October 10, 2025. <https://clinicaltrials.gov/study/NCT05934526>


Grünig E, Jansa P, Fan F, et al. Randomized trial of macitentan/tadalafil single-tablet combination therapy for pulmonary arterial hypertension. *J Am Coll Cardiol.* 2024;83(4):473-484. doi:10.1016/j.jacc.2023.10.045

Highland KB, Hughes KE, Williams KJ, Kyei-Baffour B, Ferguson S. Ensuring appropriate access to pulmonary arterial hypertension therapy. *Am J Manag Care.* 2019;25(7 Suppl):S119-S127.

Hoepfer MM, Badesch DB, Ghofrani HA, et al. Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension. *N Engl J Med.* 2023;388(16):1478-1490. doi:10.1056/NEJMoa2213558



- Hoeper MM, Dwivedi K, Pausch C, et al. Phenotyping of idiopathic pulmonary arterial hypertension: a registry analysis. *Lancet Respir Med.* 2022;10(10):937-948. doi:10.1016/S2213-2600(22)00097-2
- Hoeper MM, Gomberg-Maitland M, Badesch DB, et al. Efficacy and safety of the activin signalling inhibitor, sotatercept, in a pooled analysis of PULSAR and STELLAR studies. *Eur Respir J.* 2025;65(5):2401424. doi:10.1183/13993003.01424-2024
- Hoeper MM, Pausch C, Olsson KM, et al. COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension. *Eur Respir J.* 2022;60(1):2102311. doi:10.1183/13993003.02311-2021
- Humbert M. Viewpoint: activin signalling inhibitors for the treatment of pulmonary arterial hypertension. *Eur Respir J.* 2023;62(5):2301726. doi:10.1183/13993003.01726-2023
- Humbert M, Hassoun PM, Chin KM, et al. MK-5475, an inhaled soluble guanylate cyclase stimulator, treatment of pulmonary arterial hypertension: the INSIGNIA-PAH study. *Eur Respir J.* 2024;64(5):2401110. doi:10.1183/13993003.01110-2024
- Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension. *Eur Respir J.* 2023;61(1):2200879. doi:10.1183/13993003.00879-2022
- Humbert M, McLaughlin VV, Badesch DB, et al. Sotatercept in patients with pulmonary arterial hypertension at high risk for death. *N Engl J Med.* 2025;392(20):1987-2000. doi:10.1056/NEJMoa2415160
- International University of Health and Welfare. Satralizumab in the treatment of pulmonary arterial hypertension (SATISFY-JP Trial). Updated September 3, 2025. Accessed October 10, 2025. <https://clinicaltrials.gov/study/NCT05679570>
- Khan MS, Usman MS, Siddiqi TJ, et al. Is anticoagulation beneficial in pulmonary arterial hypertension? *Cardiovasc Qual Outcomes.* 2018;11(9):e004757. doi:10.1161/CIRCOUTCOMES.118.004757
- Khou V, Anderson JJ, Strange G, et al. Diagnostic delay in pulmonary arterial hypertension: Insights from the Australian and New Zealand pulmonary hypertension registry. *Respirology.* 2020;25(8):863-871. doi:10.1111/resp.13768
- Klinger JR, Elliott CG, Levine DJ, et al. Therapy for Pulmonary Arterial Hypertension in Adults: Update of the CHEST Guideline and Expert Panel Report. *Chest.* 2019;155(3):565-586. doi:10.1016/j.chest.2018.11.030
- Kubota K, Miyanaga S, Akao M, et al. Association of delayed diagnosis of pulmonary arterial hypertension with its prognosis. *J Cardiol.* 2024;83(6):365-370. doi:10.1016/j.jicc.2023.08.004
- Kularatne M, Gerges C, Jevnikar M, Humbert M, Montani D. Updated clinical classification and hemodynamic definitions of pulmonary hypertension and its clinical implications. *J Cardiovasc Dev Dis.* 2024;11(3):78. doi:10.3390/jcdd11030078
- Lajoie AC, Lauziere G, Lega JC, et al. Combination therapy versus monotherapy for pulmonary arterial hypertension: a meta-analysis [published correction appears in *Lancet Respir Med.* 2016;4(6):e34. doi: 10.1016/S2213-2600(16)30091-1]. *Lancet Respir Med.* 2016;4(4):291-305. doi:10.1016/S2213-2600(16)00027-8
- Liquidia Technologies, Inc. A phase 3 study to evaluate the safety and tolerability of L606 in subjects with PAH or PH-ILD. Updated October 9, 2024. Accessed October 10, 2025. <https://clinicaltrials.gov/study/NCT04691154>



Maron BA, Kovacs G, Vaidya A, et al. Cardiopulmonary hemodynamics in pulmonary hypertension and heart failure: JACC review topic of the week. *J Am Coll Cardiol*. 2020;76(22):2671-2681. doi:10.1016/j.jacc.2020.10.007

Mazurek JA, Germack HD, Gauthier-Loiselle M, et al. Impact of treatment escalation on rehospitalization among patients with pulmonary arterial hypertension. *Sci Rep*. 2025;15(1):12235. doi:10.1038/s41598-025-90975-4

McLaughlin VV, Gaine SP, Howard LS, et al. Treatment goals of pulmonary hypertension. *J Am Coll Cardiol*. 2013;62(25 Suppl):D73-D81. doi:10.1016/j.jacc.2013.10.034

Merck Sharp & Dohme LLC. MK-5475-013 INSIGNIA-PH-COPD: A study of the efficacy and safety of MK-5475 (an inhaled SGC stimulator) in adults with PH-COPD. Updated October 7, 2025. Accessed October 10, 2025. <https://clinicaltrials.gov/study/NCT05612035>

Mukherjee M, Rudski LG, Addetia K, et al. Guidelines for the Echocardiographic Assessment of the Right Heart in Adults and Special Considerations in Pulmonary Hypertension: Recommendations from the American Society of Echocardiography. *J Am Soc Echocardiogr*. 2025;38(3):141-186. doi:10.1016/j.echo.2025.01.006

Preston IR, Badesch D, Ghofani HA, et al. A long-term follow-up study of sotatercept for treatment of pulmonary arterial hypertension: Interim results of SOTERIA. *Eur Respir J*. 2025;66(1):2401435. doi:10.1183/13993003.01435-2024. Epub ahead of print.

Preston IR, Roberts KE, Miller DP, et al. Effect of warfarin treatment on survival of patients with pulmonary arterial hypertension (PAH) in the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL). *Circulation*. 2015;132(25):2403-2411. doi:10.1161/CIRCULATIONAHA.115.018435

Strange G, Fowler R, Jary C, Dalton B, Stewart S, Gabbay E. Integrated care and optimal management of pulmonary arterial hypertension. *J Multidiscip Healthc*. 2009;2:67-78. doi:10.2147/jmdh.s3085

Tamura Y, Takeyasu R, Takata T, et al. SATISFY-JP, a phase II multicenter open-label study on satralizumab, an anti-IL-6 receptor antibody, use for the treatment of pulmonary arterial hypertension in patients with immune-responsive-phenotype: Study protocol. *Pulm Circ*. 2023;13(2):e12251. doi:10.1002/pul2.12251

United Therapeutics. A study evaluating the efficacy and safety of ralinepag to improve treatment outcomes in PAH patients. Updated June 24, 2025. Accessed October 10, 2025. <https://clinicaltrials.gov/study/NCT03626688>

Wang P, Hu L, Yin Y, et al. Can anticoagulants improve the survival rate for patients with idiopathic pulmonary arterial hypertension? A systematic review and meta-analysis. *Thromb Res*. 2020;196:251-256. doi:10.1016/j.thromres.2020.08.024

Yang B, Zaki A, Oh N, et al. Role of multidisciplinary team approach in the management of chronic thromboembolic pulmonary hypertension. *JTCVS Open*. 2025;24:147-155. doi:10.1016/j.xjon.2024.12.011